comprehensive -WSS

comprehensive

author：Wikipedia 2025-09-29 01:35:01 - browse：3

U.S. Sen. Bernie Sanders sets his hands on two chairs as two people set up a board displaying a "price of drugs" chart behind him — politics coverage from STAT — Sen. Bernie Sanders has used his leadership of a Senate committee to pressure drugmakers to lower their prices. Kevin Dietsch/Getty Images

WASHINGTON — Bernie Sanders is figuring out just how far bullying drugmakers can take him.

For more than a year, Sanders has used his perch atop the Senate health committee to haul the CEOs of pharmaceutical companies that make insulin, vaccines, and more before the panel with progressively more ambitious demands related to their pricing. After a few victories he’s claimed — experts say some credit is deserved, but the full story is a bit more complicated — he’s now progressed to demanding that Novo Nordisk cut its price for its novel, wildly popular diabetes and weight-loss drugs.

Sanders (I-Vt.) is testing the limits of the powers of a Senate chairman with little hope of advancing his policy agenda legislatively. He’s threatened subpoenas, held a prominent nominee hostage, and initiated investigations to get his way. It’s a sharp departure from the modest, bipartisan ambitions that more disciplined, discreet leaders of the committee have taken in years past, and sets the bar for how much can be accomplished using the full extent of the bully pulpit.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： As AI regulations shape up, health tech startups beg for clarity

Wikipedia

WSS

In 'major milestone,' FDA approves first cell therapy for solid tumors

In 'major milestone,' FDA approves first cell therapy for solid tumors

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Medicare Advantage enrollment hits roughly 33.4 million

Researchers tackle phage therapy hurdles for wider adoption

knowledge

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

focus

Sports medicine is finally prioritizing gender equality

ProMED, early warning system on disease outbreaks, in peril

How one medical school became remarkably diverse

A new drug could help frostbite victims avoid its ravages

Medical records are filled with copy

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Medical records are filled with copy

Verily hires former Apple Health leader as chief scientific officer

Jerome Adams on the need for new antivirals for Covid

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

focus

Elevance, SCAN deals highlight health insurer acquisition scrutiny

My superpower is killing ticks

New study raises questions about niacin and heart health

Medicare Advantage enrollment grows 7.1% to 33.4 million people

A cyberattack has disrupted hospitals and health care in several states

Who is Magistrate Judge Moxila Upadhyaya in Trump's Jan. 6 case?

hotspot

focus

Wikipedia

focus